Every material Form 8-K PLIANT THERAPEUTICS, INC. has filed with the SEC since May 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pliant Therapeutics reported a second quarter 2026 net loss of $22.4 million, down from $43.3 million a year earlier, as operating expenses fell after the 2025 end of bexotegrast development in IPF and lower headcount. The company ended the quarter with $159.6 million in cash, cash equivalents and short-term investments and said that amount should fund operations into the second half of 2028. The filing did not include revenue or guidance figures.
Net loss was $22.4 million, or $0.36 per share, versus $43.3 million, or $0.71 per share, in the second quarter of 2025.
Research and development expenses were $16.7 million, down from $32.2 million; general and administrative expenses were $7.1 million, down from $13.4 million.
Cash, cash equivalents and short-term investments totaled $159.6 million as of June 30, 2026, which the company expects to fund operations into the second half of 2028.
Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. were appointed to the board; interim data from the FORTIFY trial is expected in 2027.
Effective July 9, 2026, Pliant Therapeutics increased its board from seven to nine members and appointed Robert Iannone, M.D., M.S.C.E., and Flavia Borellini, Ph.D., as directors. Borellini will chair the R&D Committee, and Iannone will join it. The filing describes director pay and stock options but does not report any financial results or changes to company operations.
Board size increased from seven to nine members, effective July 9, 2026.
Robert Iannone, M.D., M.S.C.E., appointed as a Class I director; Flavia Borellini, Ph.D., appointed as a Class II director.
Borellini named chairperson of the R&D Committee; Iannone named a member.
Each new director receives a $40,000 annual retainer and an option for 60,000 shares vesting over three years. Iannone receives an extra $7,500 retainer and Borellini an extra $15,000 for committee roles.
Pliant Therapeutics reported first quarter 2026 results on May 11, 2026, with a net loss of $20.0 million, compared with $56.2 million a year earlier. The company said the decline was driven mainly by lower operating expenses after it terminated bexotegrast development in idiopathic pulmonary fibrosis (IPF) in 2025, along with reduced personnel costs. Cash, cash equivalents and short-term investments were $172.4 million at March 31, 2026, which the company expects to fund operations into the second half of 2028.
Net loss was $20.0 million, or $0.32 per share, versus $56.2 million, or $0.92 per share, in the first quarter of 2025.
Research and development expenses were $13.6 million, down from $43.4 million, mainly due to completing BEACON-IPF close-out activities in 2025.
General and administrative expenses were $8.2 million, down from $15.5 million, mainly due to lower personnel-related costs.
First participant was dosed in the FORTIFY Phase 1b trial in April 2026; interim data are expected in 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PLIANT THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →